For the quarter ending 2025-09-30, PRLD had $20,971K increase in cash & cash equivalents over the period. -$19,115K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -19,725 | -63,316 |
| Depreciation and amortization | 425 | 868 |
| Noncash lease expense | 383 | 767 |
| Stock-based compensation | 2,423 | 7,646 |
| Amortization of premium and discount on marketable securities, net | 49 | 134 |
| Prepaid expenses and other current assets | -287 | 1,379 |
| Deferred revenue | - | 0 |
| Accounts payable | -2,429 | -2,760 |
| Accrued expenses and other liabilities | -367 | -2,098 |
| Operating lease liabilities | 63 | -100 |
| Net cash used in operating activities | -19,115 | -60,306 |
| Purchases of marketable securities | 0 | 34,127 |
| Proceeds from maturities of marketable securities | 40,091 | 107,901 |
| Purchases of property and equipment | 0 | 67 |
| Net cash provided by investing activities | 40,091 | 73,707 |
| Payment of offering costs | 0 | 0 |
| Proceeds from the issuance of common stock under espp | 0 | 92 |
| Proceeds from the issuance of common stock in connection with the exercise of stock options | 0 | 0 |
| Payment of withholding taxes related to stock-based compensation to employees | 5 | 7 |
| Principal payments on finance lease liabilities | 0 | 208 |
| Net cash used in financing activities | -5 | -123 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 20,971 | 13,278 |
| Cash and cash equivalents at beginning of period | 16,518 | - |
| Cash and cash equivalents at end of period | 50,767 | - |
Prelude Therapeutics Inc (PRLD)
Prelude Therapeutics Inc (PRLD)